Event details
We are delighted that you have registered to attend this webinar, please use your registered email to access the meeting. The webinar starts promptly at 18:30 GMT on Tuesday 26th January 2027.
MASH with moderate to advanced fibrosis is a progressive condition, and knowing when and how to act matters. In this 60-minute promotional webinar, Dr Philip Newsome (London, UK) and Dr Lance Stein (Atlanta, USA) will discuss how to recognise patients at risk, the pathway for identifying eligible patients and starting and monitoring pharmacotherapy, and what the MAESTRO-NASH, Phase 3 clinical trial (NCT03900429) outcomes mean in practice. Dr Stein will also share US clinical experience treating and managing patients with Rezdiffra®▼ (resmetirom).1
Rezdiffra® ▼ (resmetirom) is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with fibrosis stages F2 to F3).1
Meeting objectives
- Recognise the burden of disease for patients living with MASH with moderate to advanced fibrosis and the consequences of disease progression
- Understand the pathway for identifying eligible patients and initiating and monitoring pharmacotherapy in MASH
- Understand the MAESTRO-NASH outcomes and their application in the clinical decision-making of disease management
- Share US clinical experience treating and managing patients with Rezdiffra® ▼ (resmetirom)
Meeting agenda
| 18:30–18:35 | Welcome & Introductions Forename Surname TBC |
| 18:35-18:45 | Understanding disease progression in MASH with F2/F3 fibrosis Forename Surname TBC |
| 18:45–19:00 | MAESTRO-NASH Phase 3 clinical data Forename Surname TBC |
| 19:00–19:15 | Learns from US clinical experience Forename Surname TBC |
| 19:15–19:30 | Q&A and Close Forename Surname TBC |
Speakers
Dr Anand Velusamy
Consultant Endocrinologist at Guys and St Thomas’ NHS Foundation Trust, London
Dr Anand Velusamy is a Consultant Endocrinologist at Guy’s and St Thomas’ NHS Foundation Trust, London, with specialist expertise in thyroid disease, parathyroid disorders, and neuroendocrine tumours. He has advanced skills in thyroid fine needle aspiration and is an active member of the Southeast London Thyroid Cancer Network.
He has a strong focus on clinical and commercial research, working at the interface of academia and industry to drive innovation, support high-impact trials, and accelerate the translation of scientific advances into clinical practice. Dr Velusamy is a member of both the Corporate Liaison Committee and the Events and Training Committee of the Society for Endocrinology, where he contributes to strategic industry engagement, professional education, and the development of high-quality endocrine training initiatives.
Dr Alex Lewis
Consultant Endocrinologist at Manchester University NHS Foundation Trust, Manchester
Dr Alex Lewis is a Consultant Endocrinologist at Manchester University NHS Foundation Trust. He completed specialist training in diabetes, endocrinology, and internal medicine in 2021, and following a consultant appointment, he has run several projects to transform service development within the endocrinology department at Manchester Royal Infirmary. He is invested in improving care pathways for patients to ensure patients can be seen when they need to be and optimise patient safety, monitoring, experience, and outcomes in those with chronic endocrine disease.
Dr Lewis has a broad interest across endocrinology, including specialist interests in thyroid and parathyroid disease, reproductive endocrinology, and endocrine genetic syndromes. He regularly joins the regional pituitary and andrology multidisciplinary meetings to improve patient care. Dr Lewis also teaches in the undergraduate medical course at the University of Manchester Medical School and within specialist training programmes. Dr Lewis is a member of the Society for Endocrinology and has presented at international conferences on specialist interest areas.
Dr Lisa Yang
Consultant Endocrinologist at Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge
Dr Lisa Yang is a Consultant Endocrinologist at Cambridge University Hospitals NHS Trust. She co-chairs the regional adrenal MDT and leads clinics in reproductive endocrinology, bone and calcium disorders.
Dr Yang completed her specialty training in North-West London and was awarded a PhD from Imperial College London. She has authored numerous publications in the field of reproductive endocrinology, human brain function, and bone metabolism.
|
Prescribing Information (PIs) for Rezdiffra® are available below: |
|
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Madrigal on +44 800 031 8910 & medinfoeu@madrigalpharma.com |
|
▼ This medicinal product is subject to additional monitoring. Healthcare professionals are encouraged to report any suspected adverse reactions. |
|
If you have any questions or comments, please contact us on madrigalpharma@connect-dna.com. Reference: Jobe code | November 2026 |